49,281 Shares in Celcuity, Inc. $CELC Purchased by Granahan Investment Management LLC

Granahan Investment Management LLC purchased a new stake in shares of Celcuity, Inc. (NASDAQ:CELC) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 49,281 shares of the company’s stock, valued at approximately $2,434,000. Granahan Investment Management LLC owned 0.11% of Celcuity at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the business. US Bancorp DE raised its holdings in shares of Celcuity by 25.4% during the third quarter. US Bancorp DE now owns 706 shares of the company’s stock valued at $35,000 after acquiring an additional 143 shares in the last quarter. Rhumbline Advisers lifted its stake in Celcuity by 1.2% in the second quarter. Rhumbline Advisers now owns 42,697 shares of the company’s stock worth $570,000 after acquiring an additional 503 shares during the period. Ogorek Anthony Joseph NY ADV bought a new stake in Celcuity in the third quarter valued at $27,000. Intech Investment Management LLC increased its position in Celcuity by 5.2% during the 2nd quarter. Intech Investment Management LLC now owns 14,855 shares of the company’s stock valued at $198,000 after purchasing an additional 734 shares during the period. Finally, BNP Paribas Financial Markets increased its position in Celcuity by 78.9% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company’s stock valued at $35,000 after purchasing an additional 1,167 shares during the period. 63.33% of the stock is currently owned by institutional investors.

Celcuity Stock Performance

Shares of CELC opened at $114.90 on Tuesday. The company has a market cap of $5.32 billion, a price-to-earnings ratio of -31.31 and a beta of 0.38. The business’s fifty day simple moving average is $109.02 and its two-hundred day simple moving average is $87.77. Celcuity, Inc. has a 12 month low of $7.57 and a 12 month high of $120.32. The company has a current ratio of 12.26, a quick ratio of 12.26 and a debt-to-equity ratio of 2.74.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the stock. Wells Fargo & Company initiated coverage on shares of Celcuity in a research note on Friday, December 12th. They issued an “overweight” rating and a $126.00 price target for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Celcuity in a research report on Wednesday, January 21st. Needham & Company LLC upped their target price on Celcuity from $95.00 to $122.00 and gave the stock a “buy” rating in a report on Tuesday, March 10th. Wolfe Research restated an “outperform” rating and set a $110.00 price target on shares of Celcuity in a research report on Thursday. Finally, HC Wainwright reissued a “neutral” rating and set a $94.00 price objective (up from $77.00) on shares of Celcuity in a research report on Monday, November 17th. Eight equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Celcuity has a consensus rating of “Moderate Buy” and an average price target of $108.63.

Insider Activity

In related news, Director David Dalvey sold 20,000 shares of the stock in a transaction on Tuesday, January 27th. The stock was sold at an average price of $120.03, for a total transaction of $2,400,600.00. Following the sale, the director directly owned 90,000 shares of the company’s stock, valued at $10,802,700. This trade represents a 18.18% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 15.78% of the stock is currently owned by insiders.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.